Fintepla (fenfluramine) is a prescription medication primarily used for the treatment of seizures associated with Dravet syndrome, a rare and severe form of epilepsy that begins in infancy. It is an oral solution designed for daily administration. Fintepla works by modulating the activity of serotonin, a neurotransmitter in the brain that can influence seizure activity. Its effectiveness in reducing the frequency of convulsive seizures in patients with Dravet syndrome has been demonstrated in clinical trials, making it a valuable option in the management of this challenging condition. However, due to its association with potential side effects, including risks to heart health, its use is regulated and requires careful monitoring by healthcare professionals.